CO2018006930A2 - "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer" - Google Patents

"compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"

Info

Publication number
CO2018006930A2
CO2018006930A2 CONC2018/0006930A CO2018006930A CO2018006930A2 CO 2018006930 A2 CO2018006930 A2 CO 2018006930A2 CO 2018006930 A CO2018006930 A CO 2018006930A CO 2018006930 A2 CO2018006930 A2 CO 2018006930A2
Authority
CO
Colombia
Prior art keywords
cancer
treatment
thiadiazole compounds
compound
formula
Prior art date
Application number
CONC2018/0006930A
Other languages
English (en)
Spanish (es)
Inventor
Maurice Raymond Verschoyle Finlay
David Robert Perkins
Johannes Wilhelmus Maria Nissink
Piotr Antoni Raubo
Peter Duncan Smith
Andrew Bailey
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of CO2018006930A2 publication Critical patent/CO2018006930A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CONC2018/0006930A 2015-11-30 2018-06-29 "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer" CO2018006930A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30
PCT/EP2016/079253 WO2017093301A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CO2018006930A2 true CO2018006930A2 (es) 2018-10-10

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0006930A CO2018006930A2 (es) 2015-11-30 2018-06-29 "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"

Country Status (28)

Country Link
US (1) US10040789B2 (enExample)
EP (1) EP3383872B1 (enExample)
JP (1) JP6821680B2 (enExample)
KR (1) KR20180083411A (enExample)
CN (1) CN108349965B (enExample)
AR (1) AR106875A1 (enExample)
AU (1) AU2016361834B2 (enExample)
BR (1) BR112018008330B1 (enExample)
CA (1) CA3005517C (enExample)
CL (1) CL2018001409A1 (enExample)
CO (1) CO2018006930A2 (enExample)
DK (1) DK3383872T3 (enExample)
DO (1) DOP2018000135A (enExample)
EA (1) EA035519B9 (enExample)
ES (1) ES2796562T3 (enExample)
IL (1) IL259508A (enExample)
MX (1) MX2018006483A (enExample)
MY (1) MY195680A (enExample)
NI (1) NI201800063A (enExample)
NZ (1) NZ743699A (enExample)
PE (1) PE20181522A1 (enExample)
PH (1) PH12018501133A1 (enExample)
SG (1) SG11201803808VA (enExample)
SV (1) SV2018005700A (enExample)
TN (1) TN2018000118A1 (enExample)
TW (1) TW201731511A (enExample)
WO (1) WO2017093301A1 (enExample)
ZA (1) ZA201804361B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途
WO2025196447A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors
WO2025196446A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
US20170333429A1 (en) 2017-11-23
PH12018501133A1 (en) 2019-01-21
MX2018006483A (es) 2019-08-12
CA3005517C (en) 2023-12-12
US10040789B2 (en) 2018-08-07
CA3005517A1 (en) 2017-06-08
PE20181522A1 (es) 2018-09-24
DOP2018000135A (es) 2018-06-30
JP2018535235A (ja) 2018-11-29
MY195680A (en) 2023-02-03
EA035519B9 (ru) 2020-08-10
CL2018001409A1 (es) 2018-12-07
ES2796562T3 (es) 2020-11-27
AR106875A1 (es) 2018-02-28
TN2018000118A1 (en) 2019-10-04
SV2018005700A (es) 2019-03-07
IL259508A (en) 2018-07-31
TW201731511A (zh) 2017-09-16
CN108349965A (zh) 2018-07-31
SG11201803808VA (en) 2018-06-28
EP3383872B1 (en) 2020-05-20
BR112018008330A2 (pt) 2018-10-30
EA035519B1 (ru) 2020-06-29
EP3383872A1 (en) 2018-10-10
ZA201804361B (en) 2019-07-31
AU2016361834A1 (en) 2018-07-12
DK3383872T3 (da) 2020-06-08
AU2016361834B2 (en) 2019-11-14
WO2017093301A1 (en) 2017-06-08
JP6821680B2 (ja) 2021-01-27
NZ743699A (en) 2023-02-24
EA201891239A1 (ru) 2018-11-30
NI201800063A (es) 2018-10-18
KR20180083411A (ko) 2018-07-20
BR112018008330B1 (pt) 2023-03-07
CN108349965B (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
DOP2018000135A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
AR115885A1 (es) Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
GEAP202215535A (en) Compounds
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX376433B (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
AR103680A1 (es) Inhibidores selectivos de bace1
AR112392A1 (es) Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
AR094553A1 (es) Formas de oxadiazolpirazina
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
AR102053A1 (es) Eliminación de dióxido de carbono de una corriente de fluido
MX391999B (es) Piridinas y su uso en el tratamiento del cáncer.
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer